DIMENHYDRINATE- dimenhydrinate tablet
Major Pharmaceuticals

1006-Major

Drug Facts

Active ingredient (in each tablet)

Dimenhydrinate 50 mg

Purpose

Antiemetic

Uses

for the prevention and treatment of nausea, vomiting, or dizziness associated with motion sickness

Do not give to children under 2 years of age unless directed by a doctor

Ask a doctor before use if you have

■ glaucoma

■ a breathing problem such as emphysema or chronic bronchitis

■ trouble urinating due to an enlarged prostate gland

Ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers

When using this product

■ marked drowsiness may occur

■ avoid alcoholic drinks

■ alcohol, sedatives, and tranquilizers may increase drowsiness

■ use caution when driving a motor vehicle or operating machinery

If pregnant or breast-feeding, ask a health professional before use.

.

Keep out of reach of children.

In case of overdose, get medical help or contact a Poison Control Center (1-800-222-1222) right away.

Directions

■ to prevent motion sickness, the rst dose should be taken one-half to one hour before starting activity

■ **adults and children 12 years of age and over:** 1 to 2 tablets every 4-6 hours; not to exceed 8 tablets in 24 hours, or as directed by a doctor

■ **children 6 to under 12 years of age**: 1/2 to 1 tablet every 6-8 hours; not to exceed 3 tablets in 24 hours, or as directed by a doctor

■ **children 2 to under 6 years of age**: 1/2 tablet every 6-8 hours; not to exceed 1 1/2 tablets in 24 hours, or as directed by a doctor

Other information

■ each tablet contains: calcium 30 mg

■ store in a dry place at 15° – 30°C (59° – 86°F)

■ protect from moisture

■ see end -ap for expiration date and lot number

■ TAMPER EVIDENT: DO NOT USE IF OUTER PACKAGE IS OPENED OR BLISTER IS TORN OR BROKEN

croscarmellose sodium, dicalcium phosphate, magnesium stearate, microcrystalline cellulose

Questions or comments?

1-800-231-4670

KEEP OUTER PACKAGE FOR COMPLETE PRODUCT INFORMATION

*This product is not manufactured or distributed by Medtech Products Inc., owner of the registered trademark Dramamine®.

Distributed by: MAJOR® PHARMACEUTICALS
Indianapolis, IN 46268
Questions or comments?
Call (800) 616-2471
www.majorpharmaceuticals.com

MAJOR ®

NDC 0904-6772-12

Compare to the Active Ingredient in DRAMAMINE ® Original Formula*

Driminate ™

Dimenhydrinate USP, Antiemetic

For Nausea, Dizziness and Vomiting from Motion Sickness

12 Tablets 50mg Each

Use as Directed

MAJOR

Compare to the active ingredient in **DRAMAMINE®** Original Formula*

Driminate™

Dimenhydrinate USP, Antiemetic

For Nausea, Dizziness and Vomiting from Motion Sickness

12 Tablets 50 mg EACH **Use as Directed**

R52064

Exp:

Lot:

MAJOR®

NDC 0904-6772-12

Compare to the active ingredient in **DRAMAMINE®** Original Formula*

Driminate™

Dimenhydrinate USP, Antiemetic

For Nausea, Dizziness and Vomiting from Motion Sickness

12 TABLETS
50 mg EACH
Use as Directed

Distributed by: **MAJOR® PHARMACEUTICALS**
Indianapolis, IN 46268
Questions or comments?
Call (800) 616-2471
www.majorpharmaceuticals.com

Rev. 09/23 M-29

3 09046 77212 5

Drug Facts (continued)

Inactive ingredients croscarmellose sodium, dicalcium phosphate, magnesium stearate, microcrystalline cellulose

Questions or comments?
1-800-231-4670

Dimenhydrinate 50 mg	Antiemetic

Use for prevention and treatment of these symptoms associated with motion sickness:
- nausea
- vomiting
- dizziness

Warnings

Do not give to children under 2 years of age unless directed by a doctor

Ask a doctor before use if you have
- glaucoma
- a breathing problem such as emphysema or chronic bronchitis
- trouble urinating due to an enlarged prostate gland

Ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers

When using this product
- marked drowsiness may occur
- avoid alcoholic drinks
- alcohol, sedatives, and tranquilizers may increase drowsiness
- use caution when driving a motor vehicle or operating machinery

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center (1-800-222-1222) right away.

Directions

- to prevent motion sickness, the first dose should be taken one-half to one hour before starting activity
- to prevent or treat motion sickness, see below:
- **adults and children 12 years of age and over:** 1 to 2 tablets every 4-6 hours; not to exceed 8 tablets in 24 hours, or as directed by a doctor
- **children 6 to under 12 years of age:** 1/2 to 1 tablet every 6-8 hours; not to exceed 3 tablets in 24 hours, or as directed by a doctor
- **children 2 to under 6 years of age:** 1/2 tablet every 6-8 hours; not to exceed 1 1/2 tablets in 24 hours, or as directed by a doctor

Other information

- **each tablet contains:** calcium 30 mg
- store in a dry place at 15° – 30°C (59° – 86°F)
- protect from moisture
- see end flap for expiration date and lot number
- **TAMPER EVIDENT: DO NOT USE IF OUTER PACKAGE IS OPENED OR BLISTER IS TORN OR BROKEN**

DIMENHYDRINATE

dimenhydrinate tablet

Product Information

Product Type	HUMAN OTC DRUG	**Item Code (Source)**	NDC:0904-6772
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
DIMENHYDRINATE (UNII: JB937PER5C) (CHLORTHEOPHYLLINE - UNII:GE2UA340FM)	DIMENHYDRINATE	50 mg

Inactive Ingredients

Ingredient Name	Strength
CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)	
DIBASIC CALCIUM PHOSPHATE DIHYDRATE (UNII: O7TSZ97GEP)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)	

Product Characteristics

Color	white	**Score**	2 pieces
Shape	ROUND	**Size**	9mm
Flavor		**Imprint Code**	1006;1006
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0904-6772-12	1 in 1 CARTON	02/14/2019	08/31/2028
1		12 in 1 BLISTER PACK; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date

OTC Monograph Drug	M009	02/14/2019	08/31/2028

Labeler - Major Pharmaceuticals (191427277)

Revised: 8/2025 Major Pharmaceuticals